达格列净联合胰岛素治疗2型糖尿病的临床观察
|
摘要
目的观察达格列净联合胰岛素治疗2型糖尿病的疗效。方法 60例2型糖尿病患者随机采用胰岛素联合复合维生素(对照组,30例)、达格列净联合胰岛素(达格列净组,30例)治疗24周,比较治疗前后体质量指数(BMI)、血压、血糖、糖化血红蛋白、血脂变化。结果达格列净组治疗后血压、血糖、糖化血红蛋白、血脂、血糖达标时间、胰岛素每日剂量均低于对照组(P<0.01),而两组不良反应差异无统计学意义(P>0.05)。结论达格列净联合胰岛素治疗2型糖尿病疗效明显优于单用胰岛素治疗。
Objective To observe the efficacy of dapagliflozin and insulin in type 2 diabetes mellitus(T2DM).Methods Sixty patients with T2DM were randomly treated with insulin plus multivitamins(control group,n=30)and dapagliflozin plus insulin(treatment group,n=30)for 24 weeks.Body mass index(BMI),blood pressure,and serum levels of glucose,glycosylated hemoglobin and lipid were compared before and after therapy.Results Compared with control group,blood pressure,serum levels of glucose,glycosylated hemoglobin and lipid,glycemic controlling time,and daily insulin dose were remarkably reduced after therapy in treatment group(P<0.01).The adverse effects were comparable between two groups(P>0.05).Conclusion Combined use of dapagliflozin and insulin is superior to single application of insulin for treating T2DM.
Objective To observe the efficacy of dapagliflozin and insulin in type 2 diabetes mellitus(T2DM).Methods Sixty patients with T2DM were randomly treated with insulin plus multivitamins(control group,n=30)and dapagliflozin plus insulin(treatment group,n=30)for 24 weeks.Body mass index(BMI),blood pressure,and serum levels of glucose,glycosylated hemoglobin and lipid were compared before and after therapy.Results Compared with control group,blood pressure,serum levels of glucose,glycosylated hemoglobin and lipid,glycemic controlling time,and daily insulin dose were remarkably reduced after therapy in treatment group(P<0.01).The adverse effects were comparable between two groups(P>0.05).Conclusion Combined use of dapagliflozin and insulin is superior to single application of insulin for treating T2DM.
引文
[1]Diabets Federation.IDF Diabets Atlas[S].Sixth thedn,2013.
[2]A desktop guide to type 2 diabetes mellitus.European Diabetes Policy Group 1999[J].Diabet Med,1999,16(9):716-730.
[3]江范.沙格列汀或格列美脲联合甘精胰岛素对2型糖尿病患者血糖的影响[J].慢性病学杂志,2017,18(5):514-515,518.
[4]邢玉华,裴智勇,陈禹保.2型糖尿病口服降糖药药物基因组学研究进展[J].中国糖尿病杂志,2017,25(8):748-755.
[5]王艳梅,王根杰,张树林,等.临床常用降糖药物的不良反应及防治策略[J].中国医院药学杂志,2015,35(24):2233-2236.
[6]陈镇涛,王苓.吡格列酮联合二甲双胍对型糖尿病患者胰岛素抵抗及炎性因子的影响[J].广东医科大学学报,2018,36(2):138-140.
[7]Abdul-Ghani M A,Norton L,Defronzo R A.Role of sodiumglucose cotransporter 2(SGLT 2)inhibitors in the treatment of type 2 diabets[J].Endocnr Rev,2011,32(4):515-531.
[8]Santer R,Calado J.Familial renal glucosuria and SGLT2:from a mendelian trait to a therapeutic target[J].Clin J Am Soc Nephrol,2010,5(1):133-144.
[9]Garber A J,Abrahamson M J,Barzilay J I,et al.AACEcomprehensive diabets management algorithm 2013[J].Endocr Pract,2013,19(2):327-336.
[10]陈晓蕾,贾农,杨林,等.胰岛素治疗血糖控制不佳的2型糖尿病患者联合达格列净的疗效及安全性[J].糖尿病新世界,2017(11):64-66.
[11]石佳,方振威,林阳.达格列净对2型糖尿病患者血糖及心血管危险因素影响的Meta分析[J].中国临床药理学杂志,2015,31(2):116-118,134.
[12]赵惟超,项荣武,杜闪闪,等.达格列净治疗2型糖尿病有效性及安全性的Meta分析[J].沈阳药科大学学报,2017,34(10):917-928.
[2]A desktop guide to type 2 diabetes mellitus.European Diabetes Policy Group 1999[J].Diabet Med,1999,16(9):716-730.
[3]江范.沙格列汀或格列美脲联合甘精胰岛素对2型糖尿病患者血糖的影响[J].慢性病学杂志,2017,18(5):514-515,518.
[4]邢玉华,裴智勇,陈禹保.2型糖尿病口服降糖药药物基因组学研究进展[J].中国糖尿病杂志,2017,25(8):748-755.
[5]王艳梅,王根杰,张树林,等.临床常用降糖药物的不良反应及防治策略[J].中国医院药学杂志,2015,35(24):2233-2236.
[6]陈镇涛,王苓.吡格列酮联合二甲双胍对型糖尿病患者胰岛素抵抗及炎性因子的影响[J].广东医科大学学报,2018,36(2):138-140.
[7]Abdul-Ghani M A,Norton L,Defronzo R A.Role of sodiumglucose cotransporter 2(SGLT 2)inhibitors in the treatment of type 2 diabets[J].Endocnr Rev,2011,32(4):515-531.
[8]Santer R,Calado J.Familial renal glucosuria and SGLT2:from a mendelian trait to a therapeutic target[J].Clin J Am Soc Nephrol,2010,5(1):133-144.
[9]Garber A J,Abrahamson M J,Barzilay J I,et al.AACEcomprehensive diabets management algorithm 2013[J].Endocr Pract,2013,19(2):327-336.
[10]陈晓蕾,贾农,杨林,等.胰岛素治疗血糖控制不佳的2型糖尿病患者联合达格列净的疗效及安全性[J].糖尿病新世界,2017(11):64-66.
[11]石佳,方振威,林阳.达格列净对2型糖尿病患者血糖及心血管危险因素影响的Meta分析[J].中国临床药理学杂志,2015,31(2):116-118,134.
[12]赵惟超,项荣武,杜闪闪,等.达格列净治疗2型糖尿病有效性及安全性的Meta分析[J].沈阳药科大学学报,2017,34(10):917-928.